INVESTBOARDLog in
Healthcare · Medical Instruments & Supplies · US

Becton Dickinson and Company BDX

$215.25 · close of Nov 9, 2026

Regulatory and protocol barriers create durable tolls on essential medical procedures, persisting as long as hospitals prioritize safety and compliance over lowest cost.

AI score · Average · analysis Sep 18, 2026
4.2 of 10

Moat and Risk hold this up; Optionality is the soft spot.

Moat5.0
Management4.0
Valuation4.0
Risk · 10 = lowest5.0
Business model4.0
Optionality2.0
Fair value
AI fair value
$122.88
as of Nov 10, 2026
Base case
$110.78
the single most likely path
Analyst consensus
$195.57
16 analysts · 12-month target
Price
$215.25
price 75% above the AI fair value

The price needs 9.0% growth a year for ten years. The AI thinks 3.0% is achievable, at a 15.0% margin.

At a 15% margin the stock requires 9% growth to justify its price, but only 3% is achievable, producing a -6% gap that signals material overvaluation and limited upside.

The business

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Last report Nov 5, 2026

Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.

Start the thirty days · no card
General investment analysis · not personalized advice · the figures carry their dates